Trial Profile
A Study Assessing the Efficacy and Prognostic Factors in Second-Line Chemotherapy (CTX) for Elderly Patients with Metastatic Gastric Cancer (mGC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2018
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2018 New trial record
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium.